Lineage Cell Therapeutics (LCTX) Change in Receivables (2010 - 2026)
Lineage Cell Therapeutics' (LCTX) quarterly Change in Receivables came in at -$154000.0 in Q1 2026, up 63.68% year-on-year from -$94086.5 in Q1 2025, and down 118.62% quarter-over-quarter from $827000.0 in Q4 2025.
Lineage Cell Therapeutics (LCTX) Change in Receivables (2010 - 2026) Analysis & Trends
Lineage Cell Therapeutics' Change in Receivables history runs 17 years deep, the most recent figure standing at -$154000.0 for Q1 2026.
- On a quarterly basis, Change in Receivables rose 63.68% year-over-year to -$154000.0 in Q1 2026; TTM through Mar 2026 was $586000.0, a 324.64% increase from a year earlier, with the FY2025 full-year figure at $316000.0, up 398.11% from the prior year.
- Change in Receivables declined to -$154000.0 in Q1 2026 per LCTX's latest filing, from $827000.0 in the prior quarter.
- Across five years, Change in Receivables topped out at $827000.0 in Q4 2025 and bottomed at -$50.3 million in Q1 2022.
- The 5-year median for Change in Receivables is -$6000.0 (2023), against an average of -$2.9 million.
- Across the five-year window, Change in Receivables slumped 37374.81% in 2022 and jumped 2916.67% in 2024, its largest moves.
- Year by year, Change in Receivables stood at -$108000.0 in 2022, then surged by 382.41% to $305000.0 in 2023, then dropped by 23.61% to $233000.0 in 2024, then jumped by 254.94% to $827000.0 in 2025, then plunged by 118.62% to -$154000.0 in 2026.
- Per Business Quant, the three latest LCTX Change in Receivables figures stand at -$154000.0 (Q1 2026), $827000.0 (Q4 2025), and -$130000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 75.30 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 2.84 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -39.80 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -1.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Lineage Cell Therapeutics | 267.08 Mn | 203.18 Mn | 1.73 Mn | -154,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -154,000.00 |
| Mar 31, 2026 | -154,000.00 |
| Dec 31, 2025 | 827,000.00 |
| Dec 31, 2025 | 827,000.00 |
| Sep 30, 2025 | -130,000.00 |
| Sep 30, 2025 | -130,000.00 |
| Jun 30, 2025 | 43,000.00 |
| Jun 30, 2025 | 43,000.00 |
| Mar 31, 2025 | -424,000.00 |
| Mar 31, 2025 | -424,000.00 |
| Dec 31, 2024 | 233,000.00 |
| Dec 31, 2024 | 233,000.00 |
| Sep 30, 2024 | 169,000.00 |
| Sep 30, 2024 | 169,000.00 |
| Jun 30, 2024 | 160,000.00 |
| Jun 30, 2024 | 160,000.00 |
| Mar 31, 2024 | -668,000.00 |
| Mar 31, 2024 | -668,000.00 |
| Dec 31, 2023 | 305,000.00 |
| Dec 31, 2023 | 305,000.00 |